Cellectar Biosciences, Inc.
CLRB
$3.69
$0.071.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.33M | 3.65M | 2.97M | 6.54M | 7.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.85M | 6.04M | 6.40M | 12.74M | 13.33M |
| Operating Income | -4.85M | -6.04M | -6.40M | -12.74M | -13.33M |
| Income Before Tax | -4.44M | -5.45M | -6.60M | -2.29M | -14.66M |
| Income Tax Expenses | -- | -- | -- | 66.00K | -- |
| Earnings from Continuing Operations | -4.44M | -5.45M | -6.60M | -2.36M | -14.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.44M | -5.45M | -6.60M | -2.36M | -14.66M |
| EBIT | -4.85M | -6.04M | -6.40M | -12.74M | -13.33M |
| EBITDA | -4.80M | -5.98M | -6.34M | -12.68M | -13.26M |
| EPS Basic | -1.41 | -3.39 | -4.30 | -1.68 | -11.18 |
| Normalized Basic EPS | -0.88 | -2.12 | -2.69 | -1.02 | -6.99 |
| EPS Diluted | -1.41 | -3.39 | -4.30 | -1.68 | -12.13 |
| Normalized Diluted EPS | -0.88 | -2.12 | -2.69 | -1.02 | -6.91 |
| Average Basic Shares Outstanding | 3.16M | 1.61M | 1.54M | 1.40M | 1.31M |
| Average Diluted Shares Outstanding | 3.16M | 1.61M | 1.54M | 1.40M | 1.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |